Vireo Growth Inc. Announces Fourth Quarter 2025 Results

Vireo Growth Inc. Announces Fourth Quarter 2025 Results 03/17/2026 Q4 GAAP revenue of $104.5 million increased 317.7% year-over-year, driven by recently closed M&A transactions On a pro forma basis, Q4 same store sales increased 22% year-over-year and wholesale revenue increased 55% year-over-year; excluding Minnesota, same store sales increased 11.3% year-over-year Announced the pending acquisitions of Eaze, Schwazze, and PharmaCann retail assets in Colorado, and MOU for the acquisition of Hawthorne, all of which are expected to close in the first half of 2026 Company closed Q4 with $122.5 million in cash; expects to remain acquisitive MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its fourth fiscal quarter ended December 31, 2025. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars. Year-over-Year Performance Summary Three Months EndedUS $ in millionsDecember 31, 2025 2024 VarianceGAAP Revenue$104.5 $25.0 317.7% GAAP Gross Profit$56.9 $12.7 348.0% Gross Profit Margin 54.4% 50.6% 380 bpsAdjusted Gross Profit(1)$58.8 $12.8 359.4% Adjusted Gross Profit Margin(1) 56.3% 51.2% 510 bpsAdjusted EBITDA (non-GAAP)(3)$29.5 $6.6 347.0% Adjusted EBITDA Margin(3) 28.2% 26.4% 180 bps Three Months EndedUS $ in millionsDecember 31, 2025 2024 VariancePro Forma Revenue(2)$104.5 $82.9 26.1% Pro Forma Adjusted EBITDA(3)(2)$29.5 $22.7 30.0% Pro Forma Adjusted EBITDA Margin(3)(2) 28.2% 27.4% 80 bps 1Non-GAAP measure. Excludes fair value adjustments and non-cash product costs. 2Pro forma results give effect to the mergers of Deep Roots, Proper, and Wholesome (the “Mergers”) as if they were completed on October 1, 2024. Pro forma information has been presented for informational purposes only and is not necessarily indicative of the Company’s past results of operations, nor is it indicative of the future operating results of the Company and should not be considered a substitute for the financial information presented in accordance with GAAP. 3Non-GAAP measure. See Supplemental Information and Reconciliation of Non-GAAP Financial Measures. Sequential Performance Summary US $ in millionsThree Months Ended December 31, 2025 September 30, 2025 VarianceGAAP Revenue$104.5 $91.7 14.0% GAAP Gross Profit$56.9 $37.4 52.1% Gross Profit Margin 54.4% 40.8% 1,360 bpsAdjusted Gross Profit(1)$58.8 $50.8 15.7% Adjusted Gross Profit Margin(1) 56.3% 55.4% 90 bpsAdjusted EBITDA (non-GAAP)(2)$29.5 $25.4 16.1% Adjusted EBITDA Margin(2) 28.2% 27.7% 50 bps 1Non-GAAP measure. Excludes fair value adjustments and non-cash product costs. 2Non-GAAP measure. See Supplemental Information and Reconciliation of Non-GAAP Financial Measures. Management Commentary Chief Executive Officer John Mazarakis commented, “Fourth quarter performance remained in line with our expectations and reflected pro forma same store sales growth excluding Minnesota of 11.3% and wholesale growth of 55% over the prior year quarter. As we begin the new year, we will continue optimizing all areas of our business while remaining opportunistic with respect to further acquisition related growth opportunities.” Recent Developments On December 16, 2025, the Company entered into an asset purchase agreement through a wholly owned subsidiary to acquire certain assets and properties used in cannabis dispensaries operated in the State of Colorado owned by PharmaCann Inc. (“PharmaCann”). Under the terms of the agreement, the Company expects to issue subordinate voting shares with an estimated value of $49,000,000 and assume certain liabilities as consideration for the acquired assets. The share consideration is subject to certain adjustments. On December 22, 2025, the Company entered into an agreement and plan of merger to acquire Eaze Inc. (“Eaze”) in a business combination transaction. Pursuant to the agreement, following the closing of the transaction, the Company expects to issue subordinate voting shares as consideration for all of the issued and outstanding equity interests of Eaze. The estimated closing consideration is approximately $47,000,000, subject to customary post-closing adjustments. The merger agreement also provides for potential earnout consideration payable in the Company’s subordinate voting shares based on Eaze’s future financial performance, subject to contractual limitations. On January 15, 2026, the Company entered into a nonbinding Memorandum of Understanding (“MOU”) with ScottsMiracle-Gro related to the potential acquisition of The Hawthorne Gardening Company LLC (“Hawthorne”). At the end of the fourth quarter, the Company had completed the integration of its recent acquisitions of Deep Roots, Proper, and Wholesome, including streamlined accounting, finance, human resources, insurance, and procurement operations, as well as the implementation of a new Enterprise Resource Planning system across the organization. The Company has already realized corporate overhead synergies as a result. Balance Sheet and Liquidity As of December 31, 2025, total current assets excluding the notes receivable of Medicine Man Technologies Inc. (dba Schwazze) (“Schwazze”), assets held for sale, and income taxes receivable were $204.1 million, including cash on hand of $122.5 million. Total current liabilities excluding uncertain tax liabilities were $71.6 million. As of December 31, 2025, the Company had a total of 1,177,624,278 subordinate voting shares outstanding on the treasury method basis using a share price of $0.60. Conference Call and Webcast Information Vireo management will host a conference call with research analysts today, March 17, 2026, at 8:00 a.m. ET (7:00 a.m. CT) to discuss its financial results for its fourth quarter ended December 31, 2025. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 9471311. A live audio webcast of this event will also be available in the Events & Presentations section of the Company’s Investor Relations website and via the following link: https://events.q4inc.com/attendee/171708452. About Vireo Growth Inc. Vireo was founded in 2014 as a pioneering medical cannabis company. Vireo is building a disciplined, strategically aligned, and execution-focused platform in the industry. This strategy drives our intense local market focus while leveraging the strength of a national portfolio. We are committed to hiring industry leaders and deploying capital and talent where we believe it will drive the most value. Vireo operates with a long-term mindset, a bias for action, and an unapologetic commitment to its customers, employees, shareholders, industry collaborators, and the communities it serves. For more information about Vireo, visit www.vireogrowth.com. Additional Information Additional information relating to the Company’s fourth quarter 2025 results will be available on EDGAR and SEDAR+ later today. Vireo refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, and Adjusted Gross Profit Margin in circumstances in which the Company believes that doing so provides additional perspective and insights when analyzing the core operating performance of the business. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures including a reconciliation of each measure to the most directly comparable GAAP financial measure. Contact Information Joe Duxbury Chief Accounting Officer [email protected] (612) 314-8995 Forward-Looking Statement Disclosure This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding the Company’s future M&A strategy and optimization of all areas of the Company’s business; the Company’s expectations around its pending transactions with PharmaCann, Schwazze and Eaze; and expectations around the proposed transaction involving Hawthorne. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue, EBITDA, Adjusted EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the fact that the MOU with ScottsMiracle-Gro is non-binding and there can be no assurance that the parties will enter into a definitive agreement; risks related to management's ability to negotiate a definitive agreement with ScottsMiracle-Gro on acceptable terms or at all; risks related to receipt of necessary regulatory and third-party approvals for completion of the Company’s pending and proposed transactions; risks and uncertainties associated with the pending transactions with Schwazze, PharmaCann, and Eaze and the proposed transaction with ScottsMiracle-Gro, some of which are beyond the Company’s control; the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties as a result of the pending transactions with Schwazze, PharmaCann and Eaze and proposed transaction with ScottsMiracle-Gro; the effects of the pending transactions with Schwazze, PharmaCann, and Eaze and proposed transaction with ScottsMiracle-Gro on the Company and the interests of various constituents; subject to the successful outcome of the pending transactions with Schwazze, PharmaCann, and Eaze and proposed transaction with ScottsMiracle-Gro, the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in its various markets; the Company’s ability to dispose of its assets held for sale at an acceptable price or at all; and risk factors set out in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.com. The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements. VIREO GROWTH INC. STATE-BY-STATE REVENUE PERFORMANCE THREE MONTHS ENDED DECEMBER 31, 2025, 2024 PRO FORMA, AND 2024 Three Months Ended December 31, 2025 2024 (pro forma)1 $ Change % Change Retail: MN $18,863,457 $11,221,254 $7,642,203 68 %NY 923,579 1,307,983 (384,404) (29)%MD 6,925,872 6,846,072 79,800 1 %UT 12,008,798 10,676,764 1,332,034 12 %NV 27,930,111 23,785,577 4,144,534 17 %MO 21,323,106 18,328,070 2,995,036 16 %Total Retail $87,974,923 $72,165,720 $15,809,203 22 % Wholesale: MN $98,993 133,606 (34,613) (26)%NY 6,838,607 1,499,647 5,338,960 356 %MD 3,496,948 4,014,754 (517,806) (13)%UT 2,021,769 1,644,832 376,937 23 %NV 53,845 350,631 (296,786) (85)%MO 4,025,377 3,045,323 980,054 32 %Total Wholesale $16,535,539 $10,688,793 $5,846,746 55 % Total Revenue $104,510,462 $82,854,513 $21,655,949 26 % 1Pro forma results give effect to the Mergers as if they were completed on October 1, 2024. Pro forma information has been presented for informational purposes only and is not necessarily indicative of the Company’s past results of operations, nor is it indicative of the future operating results of the Company and should not be considered a substitute for the financial information presented in accordance with GAAP. Three Months Ended December 31, 2025 2024 $ Change % Change Retail: MN $18,863,457 $11,221,254 $7,642,203 68 %NY 923,579 1,307,983 (384,404) (29)%MD 6,925,872 6,846,072 79,800 1 %UT 12,008,798 — 12,008,798 100 %NV 27,930,111 — 27,930,111 100 %MO 21,323,106 — 21,323,106 100 %Total Retail $87,974,923 $19,375,309 $68,599,614 354 % Wholesale: MN $98,993 133,606 (34,613) (26)%NY 6,838,607 1,499,647 5,338,960 356 %MD 3,496,948 4,014,754 (517,806) (13)%UT 2,021,769 — 2,021,769 100 %NV 53,845 — 53,845 100 %MO 4,025,377 — 4,025,377 100 %Total Wholesale $16,535,539 $5,648,007 $10,887,532 193 % Total Revenue $104,510,462 $25,023,316 $79,487,146 318 % Supplemental Information and Reconciliation of Non-GAAP Financial Measures Vireo management occasionally elects to provide certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, and Adjusted Operating Income Margin. EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, and Adjusted Operating Income Margin are non-GAAP measures and do not have standardized definitions under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented. Reconciliation of Net Loss to EBITDA and Adjusted EBITDA We have included this information as management believes certain investors use this information to evaluate our performance in comparison to other cannabis companies. The table below provides a reconciliation of net loss to EBITDA and to Adjusted EBITDA. Three Months Ended December 31, 2025 2024 2024 (pro-forma)1Net income (loss) $(20,372,228) $(15,701,281) $(20,841,392)Interest expense, net 8,100,800 7,584,099 9,655,466 Income taxes 8,327,000 4,343,000 11,660,843 Depreciation & Amortization 13,643,376 249,964 2,944,346 Depreciation and amortization included in cost of sales 1,628,983 590,433 398,370 EBITDA (non-GAAP) $11,327,931 $(2,933,785) $3,817,633 Non-cash inventory adjustments 1,911,502 164,000 1,083,134 Stock-based compensation 9,045,515 2,203,634 6,768,568 Change in the fair value of contingent consideration 9,617,000 — — Transaction related expenses 4,430,409 4,227,497 6,173,438 Other expense (income) (9,515,623) 2,932,632 3,328,341 Loss on impairment 2,600,000 — — Severance expense 35,850 — — Loss on disposal of assets 23,482 — 1,496,053 Adjusted EBITDA (non-GAAP) $29,476,066 $6,593,978 $22,667,167 1Pro forma results give effect to the Mergers of Deep Roots, Proper, and Wholesome as if they were completed on October 1, 2024. Pro forma information has been presented for informational purposes only and is not necessarily indicative of the Company’s past results of operations, nor is it indicative of the future operating results of the Company and should not be considered a substitute for the financial information presented in accordance with GAAP The financial information reported in this news release is based on the audited statements for the years ended December 31, 2025, and 2024, and the unaudited financial statements for the fourth quarters ended December 31, 2025 and 2024. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company’s audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company’s audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. VIREO GROWTH INC. CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2025 AND 2024 (Amounts Expressed in United States Dollars, Audited and Condensed) December 31, December 31, 2025 2024 Assets Current assets: Cash $102,229,759 $91,604,970 Restricted Cash 20,265,212 — Marketable Securities 1,020,243 — Accounts receivable, net of credit losses of $1,266,965 and $244,264, respectively 13,761,917 4,590,351 Income tax receivable 22,756,544 12,027,472 Inventory 59,969,928 21,666,364 Prepayments and other current assets 3,896,577 1,650,977 Warrants held 1,684,691 2,270,964 Notes receivable 79,226,015 — Assets held for sale 300,000 96,560,052 Total current assets 305,110,886 230,371,150 Property and equipment, net 217,505,538 32,311,762 Operating lease, right-of-use asset 53,368,204 7,859,434 Intangible assets, net 117,471,678 7,899,328 Goodwill 87,534,561 — Investments 6,000,000 — Deposits 4,390,559 421,244 Indemnified tax assets 25,772,866 — Total assets $817,154,292 $278,862,918 Liabilities Current liabilities Accounts payable and accrued liabilities $50,254,506 $10,456,036 Convertible debt, current portion 1,300,000 — Long-term debt, current portion 16,290,000 900,000 Right of use liability, current 3,556,576 1,400,015 Uncertain tax liability 119,954,000 33,324,000 Derivative liability 172,811 — Liabilities held for sale — 89,387,203 Total current liabilities 191,527,893 135,467,254 Right-of-use liability 146,308,253 16,494,439 Long-term debt, net 127,644,855 61,438,046 Convertible debt, net 8,600,000 9,862,378 Contingent consideration 24,448,000 — Deferred tax liabilities 10,217,000 — Other long-term liabilities 983,299 37,278 Total liabilities 509,729,300 223,299,395 Commitments and contingencies Stockholders’ equity Subordinate Voting Shares ($- par value, unlimited shares authorized; 1,057,131,571 shares issued and outstanding at December 31, 2025 and 337,512,681 at December 31, 2024) — — Multiple Voting Shares ($- par value, unlimited shares authorized; 233,192 shares issued and outstanding at December 31, 2025 and 285,371 at December 31, 2024) — — Additional paid in capital 606,974,461 286,999,084 Accumulated deficit (299,549,469) (231,435,561)Total stockholders' equity $307,424,992 $55,563,523 Total liabilities and stockholders' equity $817,154,292 $278,862,918 VIREO GROWTH INC. CONSOLIDATED STATEMENTS OF OPERATIONS THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025 AND 2024 (Amounts Expressed in United States Dollars, Audited and Condensed) Unaudited Three Months Ended December 31, Audited Year Ended December 31, 2025 2024 2025 2024 Revenue $104,510,462 $25,023,316 $268,769,268 $99,384,221 Cost of sales Product costs 45,716,741 12,207,339 122,009,304 48,319,204 Non-cash product costs 1,255,533 — 17,805,282 — Inventory valuation adjustments 655,969 164,000 1,859,305 294,000 Gross profit 56,882,219 12,651,977 127,095,377 50,771,017 Operating expenses: Selling, general and administrative expenses 31,577,357 6,812,432 81,186,632 28,063,050 Transaction related expenses 4,430,409 4,227,497 11,208,273 4,504,001 Stock-based compensation expenses 9,045,515 2,203,634 18,663,707 3,627,774 Depreciation 10,320,310 69,931 11,337,597 292,694 Amortization 3,323,066 180,033 5,747,651 720,134 Total operating expenses 58,696,657 13,493,527 128,143,860 37,207,653 Income (loss) from operations (1,814,438) (841,550) (1,048,483) 13,563,364 Other income (expense): Interest expenses, net (4,502,233) (4,016,462) (15,905,534) (16,966,678)Interest expense on finance lease liabilities - Minnesota & New York (3,598,567) (3,567,637) (14,348,831) (14,222,167)Impairment of long-lived assets (2,600,000) — (2,600,000) — Gain (loss) on disposal of assets and debt (23,482) — (7,866,997) (218,327)Gain (loss) on change in the fair value of contingent consideration (9,617,000) — (9,617,000) — Derivative gain (loss) (172,811) — (172,811) — Other income (expenses) 10,283,303 (2,932,632) 11,648,748 949,299 Other income (expenses), net (10,230,790) (10,516,731) (38,862,425) (30,457,873) Loss before income taxes (12,045,228) (11,358,281) (39,910,908) (16,894,509) Deferred income tax recoveries (expenses) 13,406,000 — 13,406,000 — Current income tax expenses (21,733,000) (4,343,000) (41,609,000) (11,113,000)Net loss and comprehensive loss (20,372,228) (15,701,281) (68,113,908) (28,007,509)Net loss per share - basic and diluted $(0.02) $(0.07) $(0.09) $(0.16)Weighted average shares used in computation of net loss per share - basic and diluted 1,052,500,109 232,645,863 734,738,785 180,391,815 VIREO GROWTH INC. CONSOLIDATED STATEMENTS OF CASH FLOWS YEAR ENDED DECEMBER, 2025 AND 2024 (Amounts Expressed in United States Dollars, Audited and Condensed) Year Ended December 31, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $(68,113,908) $(28,007,509)Adjustments to reconcile net loss to net cash used in operating activities: Non-cash amortization of inventory step up included in product costs 17,805,282 — Inventory valuation adjustments 1,859,305 294,000 Depreciation 11,337,597 292,694 Depreciation capitalized into inventory 4,771,998 2,244,087 Non-cash operating lease expense 2,440,134 439,664 Amortization of intangible assets 5,747,651 720,134 Amortization of intangible assets capitalized into inventory 99,116 99,116 Stock-based payments 12,946,707 3,537,774 Warrants held 586,273 (333,612)Derivative (gain) loss 172,811 — Loss on extinguishment of debt 4,911,988 — Loss on impairment of long-lived assets 2,600,000 — Interest Expense 3,908,763 4,794,018 Bad debt expense 605,443 237,873 Accretion of interest on right-of-use finance lease liabilities 575,677 221,010 (Gain) loss on change in the fair value of contingent consideration 9,617,000 — Non-cash gain on legal settlement (8,172,587) — Loss (gain) on disposal of assets (771,738) 121,756 Change in operating assets and liabilities: Accounts Receivable (6,063,868) (1,030,224)Prepaid expenses 222,735 (164,564)Inventory (8,704,956) (2,391,818)Purchase of marketable securities (1,020,243) — Income taxes 8,111,049 250,646 Deferred income tax expense (benefit) (13,406,000) — Uncertain tax position liabilities 33,477,000 10,968,000 Accounts payable and accrued liabilities (8,716,947) 2,403,710 Changes in operating lease liabilities (3,114,791) (277,851)Change in assets and liabilities held for sale — (4,653,454)Net cash provided by (used in) operating activities 3,711,491 (10,234,550) CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property, plant, and equipment (28,324,056) (11,694,966)Proceeds from note receivable — 3,600,000 Acquisition of WholesomeCo, Inc., net of cash paid 7,025,811 — Acquisition of Deep Roots Holdings, Inc., net of cash paid 19,382,757 — Acquisition of Proper Holdings Management, Inc., net of cash paid 12,951,202 — Capitalized software development costs (1,492,617) — Proceeds from sale of assets held for sale 250,000 — Deposits (1,033,646) (37,600)Net cash provided by (used in) investing activities 8,759,451 (8,132,566) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from long-term debt, net of issuance costs 146,039,514 4,668,730 Proceeds from convertible debt, net of issuance costs — 9,854,283 Proceeds from issuance of shares — 80,828,687 Proceeds from warrant exercises 38,516 69,663 Proceeds from option exercises 121,721 16,500 Debt principal payments (127,780,692) (1,234,000)Lease principal payments — (196,442)Net cash provided by (used in) financing activities 18,419,059 94,007,421 Net change in cash 30,890,001 75,640,305 Cash and restricted cash, beginning of period 91,604,970 15,964,665 Cash and restricted cash, end of period $122,494,971 $91,604,970 Source: Vireo Growth Inc.